^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QTX3034
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Quanta Therap
Drug class:
KRAS G12D inhibitor, KRAS inhibitor
Related drugs:
Phase 1
Quanta Therapeutics
Recruiting
Last update posted :
05/29/2024
Initiation :
02/05/2024
Primary completion :
04/01/2027
Completion :
04/01/2027
KRAS
|
Erbitux (cetuximab) • QTX3034
Share
